医学
斑贴试验
吡罗昔康
布洛芬
双氯芬酸
接触性皮炎
皮肤病科
过敏
接触性过敏
过敏性接触性皮炎
氟苯那酸
吲哚美辛
止痛药
麻醉
药理学
环氧合酶
前列腺素内过氧化物合酶
病理
免疫学
化学
生物化学
替代医学
酶
作者
B Gniazdowska,Franziska Ruëff,Bernhard Przybilla
标识
DOI:10.1111/j.1600-0536.1999.tb05992.x
摘要
Several non-steroidal anti-inflammatory drugs (NSAIDs) are available for topical treatment of acute soft tissue trauma or degenerative musculoskeletal disorders; the NSAID bufexamac is mainly used for therapy of chronic inflammatory skin diseases. In order to assess the occurrence of contact allergy to NSAIDs in 371 consecutive patients presenting for diagnosis of presumed contact allergy, patch tests were performed with a standard series and additionally with a series of NSAIDs, comprising acetylsalicylic acid, bufexamac, diclofenac, etofenamate, felbinac, flufenamic acid, ibuprofen, indomethacin, and piroxicam. 17 individuals (4.6%) exhibited delayed hypersensitivity to one of the NSAID preparations: 12 patients (3.2%) had patch test reactions to bufexamac, 2 (0.5%) to etofenamate, 2 (0.5%) to indomethacin, and 1 patient (0.3%) to flufenamic acid. These patch test results corresponded well to the individual history in 11 individuals (including 10 patients with reactions to bufexamac), and in 2 patients the clinical relevance of the reactions was probable. In view of the high frequency of allergic contact reactions to bufexamac, we propose to test this drug particularly in patients with atopic eczema or other chronic eczematous diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI